Literature DB >> 6882617

Absorption of orally administered amphotericin B lozenges.

M S Ching, K Raymond, R W Bury, M L Mashford, D J Morgan.   

Abstract

The systemic absorption of amphotericin B, administered as a 10 mg lozenge, was investigated in 14 patients with malignancies, who received three or four doses daily during chronic administration. The mean plasma amphotericin B concentration, measured 3 h after the morning dose on from 1-20 occasions over a 1-80 day period, ranged among subjects from 46 +/- 13 ng/ml (s.d., n = 20) to 136 +/- 25 ng/ml (n = 19). Using the previously reported intravenous clearance of the drug, the fraction of the dose absorbed was estimated at 8.3-9.9%. This is considerably greater than that estimated from earlier reports (0.2-0.9%), which used much higher oral doses (2-10 g/day).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6882617      PMCID: PMC1427953          DOI: 10.1111/j.1365-2125.1983.tb02152.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  Oral administration of solubilized amphotericin B.

Authors:  H M KRAVETZ; V T ANDRIOLE; M A HUBER; J P UTZ
Journal:  N Engl J Med       Date:  1961-07-27       Impact factor: 91.245

2.  Coccidioidomycosis and its treatment with amphotericin B.

Authors:  M L LITTMAN; P L HOROWITZ; J G SWADEY
Journal:  Am J Med       Date:  1958-04       Impact factor: 4.965

3.  Some aspects of the absorption, distribution, and excretion of amphotericin B in man.

Authors:  D B LOURIA
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1958-05

4.  Amphotericin B pharmacokinetics in humans.

Authors:  A J Atkinson; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

  4 in total
  6 in total

1.  Poor and unusually prolonged oral absorption of amphotericin B in rats.

Authors:  G Robbie; T C Wu; W L Chiou
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.

Authors:  R Santangelo; P Paderu; G Delmas; Z W Chen; R Mannino; L Zarif; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs.

Authors:  R M Fielding; A W Singer; L H Wang; S Babbar; L S Guo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

4.  Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.

Authors:  Joel B Epstein; Edmond L Truelove; Kimberly Hanson-Huggins; Lloyd A Mancl; Alice Chen; Oliver W Press; Stephen H Petersdorf; Thomas R Fritsche; Joshua D Epstein
Journal:  Support Care Cancer       Date:  2004-04-24       Impact factor: 3.603

Review 5.  Treatment of Aspergillosis.

Authors:  Jeffrey D Jenks; Martin Hoenigl
Journal:  J Fungi (Basel)       Date:  2018-08-19

6.  Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity.

Authors:  Shabi Parvez; Ganesh Yadagiri; Archana Karole; Om Prakash Singh; Anurag Verma; Shyam Sundar; Shyam Lal Mudavath
Journal:  Front Cell Infect Microbiol       Date:  2020-10-15       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.